Kensei Yamaguchi Selected Research

Oxaliplatin (Eloxatin)

8/2022	Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer.
1/2022	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
1/2022	A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma.
1/2021	The Combined Use of 5 or More Drugs Is a Factor Related to Lower Adherence to S-1 in S-1 and Oxaliplatin Treatment for Advanced Gastric Cancer.
4/2020	Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study.
1/2020	Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
1/2020	A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.
11/2019	Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer.
9/2019	Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer.
8/2019	Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kensei Yamaguchi Research Topics

Disease

75	Stomach Neoplasms (Stomach Cancer) 07/2022 - 01/2002
71	Neoplasms (Cancer) 08/2022 - 09/2004
71	Colorectal Neoplasms (Colorectal Cancer) 06/2022 - 07/2006
19	Neoplasm Metastasis (Metastasis) 06/2022 - 10/2013
17	Adenocarcinoma 08/2022 - 11/2009
17	Disease Progression 01/2022 - 11/2009
15	Neutropenia 11/2021 - 08/2012
6	Diarrhea 12/2018 - 11/2011
5	Febrile Neutropenia 01/2022 - 01/2006
5	Esophageal Squamous Cell Carcinoma 10/2021 - 01/2017
4	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 02/2014
4	Anemia 01/2020 - 12/2013
4	Microsatellite Instability 04/2019 - 12/2014
4	Colonic Neoplasms (Colon Cancer) 01/2019 - 07/2006
4	Carcinoma (Carcinomatosis) 01/2017 - 08/2006
3	Breast Neoplasms (Breast Cancer) 04/2022 - 11/2018
3	Rectal Neoplasms (Rectal Cancer) 01/2022 - 11/2011
3	Esophageal Neoplasms (Esophageal Cancer) 10/2021 - 05/2020
3	Hypertension (High Blood Pressure) 01/2021 - 03/2018
3	Lymphatic Metastasis 11/2020 - 11/2011
3	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 10/2020 - 03/2009
3	Ascites 01/2020 - 01/2018
3	Anorexia 01/2018 - 10/2013
3	Fatigue 01/2018 - 08/2012
2	Carcinogenesis 06/2022 - 01/2010
2	Residual Neoplasm 03/2020 - 11/2019
2	Hypersensitivity (Allergy) 01/2020 - 01/2002
2	Vomiting 11/2017 - 09/2004

Drug/Important Bio-Agent (IBA)

24	Oxaliplatin (Eloxatin)FDA LinkGeneric 08/2022 - 11/2008
22	Cisplatin (Platino)FDA LinkGeneric 08/2022 - 01/2006
20	Fluorouracil (Carac)FDA LinkGeneric 05/2022 - 11/2009
20	Irinotecan (Camptosar)FDA LinkGeneric 04/2020 - 01/2007
15	Cetuximab (Erbitux)FDA Link 06/2022 - 11/2008
15	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2014
14	Trastuzumab (Herceptin)FDA Link 04/2022 - 07/2012
13	Leucovorin (Folinic Acid)FDA Link 11/2021 - 09/2010
12	NivolumabIBA 07/2022 - 01/2017
12	RamucirumabIBA 07/2022 - 07/2016
12	Capecitabine (Xeloda)FDA Link 01/2022 - 07/2006
12	Bevacizumab (Avastin)FDA Link 01/2022 - 10/2010
12	Paclitaxel (Taxol)FDA LinkGeneric 11/2021 - 01/2002
11	S-1 plus cisplatinIBA 01/2022 - 07/2012
10	ErbB Receptors (EGF Receptor)IBA 06/2022 - 08/2013
10	PlatinumIBA 05/2022 - 08/2013
9	trifluridine tipiracil drug combinationIBA 11/2021 - 10/2012
8	regorafenibIBA 10/2021 - 06/2016
7	Monoclonal AntibodiesIBA 01/2022 - 10/2017
7	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2010
6	human ERBB2 proteinIBA 08/2022 - 08/2017
6	Circulating Tumor DNAIBA 12/2021 - 01/2019
6	Pharmaceutical PreparationsIBA 03/2020 - 08/2012
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2021 - 06/2016
4	pembrolizumabIBA 08/2022 - 01/2017
4	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2019
4	trastuzumab deruxtecanIBA 01/2021 - 01/2019
4	CreatinineIBA 01/2019 - 07/2016
4	XELOXIBA 05/2018 - 10/2010
4	ChemokinesIBA 06/2016 - 07/2008
4	NucleolinIBA 05/2014 - 01/2010
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2010 - 01/2006
3	B7-H1 AntigenIBA 08/2022 - 01/2021
3	Tumor Biomarkers (Tumor Markers)IBA 12/2021 - 11/2018
3	Panitumumab (Vectibix)FDA Link 07/2021 - 06/2016
3	LigandsIBA 01/2021 - 06/2016
3	Therapeutic UsesIBA 01/2021 - 11/2017
3	Epidermal Growth Factor (EGF)IBA 01/2021 - 07/2012
3	NF-kappa B (NF-kB)IBA 06/2010 - 01/2006
2	C-Reactive ProteinIBA 04/2022 - 01/2022
2	andecaliximabIBA 01/2022 - 01/2022
2	EnzymesIBA 01/2022 - 09/2004
2	IpilimumabIBA 01/2022 - 10/2017
2	Carcinoembryonic AntigenIBA 12/2021 - 11/2018
2	afliberceptIBA 01/2021 - 08/2013
2	CarbohydratesIBA 11/2020 - 11/2018
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2020 - 05/2014
2	HLA Antigens (Human Leukocyte Antigens)IBA 05/2020 - 04/2020
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 04/2020 - 01/2006
2	taxaneIBA 02/2020 - 01/2017
2	DNA (Deoxyribonucleic Acid)IBA 10/2019 - 11/2013
2	AntibodiesIBA 01/2019 - 11/2017
2	Leucine (L-Leucine)FDA Link 11/2018 - 01/2007
2	Codon (Codons)IBA 09/2013 - 01/2007

Therapy/Procedure

79	Drug Therapy (Chemotherapy) 08/2022 - 01/2002
46	Therapeutics 01/2022 - 01/2002
9	Adjuvant Chemotherapy 01/2022 - 07/2006
7	Combination Drug Therapy (Combination Chemotherapy) 05/2022 - 07/2007
5	Gastrectomy 12/2021 - 11/2018
4	Chemoradiotherapy 01/2022 - 11/2011
4	Neoadjuvant Therapy 01/2022 - 06/2019
3	Immunotherapy 01/2021 - 04/2020
2	Aftercare (After-Treatment) 01/2022 - 11/2019
2	Intravenous Infusions 01/2022 - 08/2012
2	Precision Medicine 01/2022 - 11/2021
2	Hepatectomy 11/2020 - 11/2013
2	Treatment Delay 01/2020 - 11/2011
2	Molecular Targeted Therapy 02/2017 - 04/2011
2	Salvage Therapy 06/2016 - 06/2016
2	Oral Administration 02/2014 - 11/2009
2	Drug Tapering 02/2014 - 11/2011
2	Premedication 08/2012 - 01/2002